{"id":"NCT01099774","sponsor":"Allergan","briefTitle":"Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05-01","primaryCompletion":"2011-04-29","completion":"2011-04-29","firstPosted":"2010-04-08","resultsPosted":"2012-04-27","lastUpdate":"2019-04-17"},"enrollment":597,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Bimatoprost 0.03% Formulation B Ophthalmic Solution","otherNames":[]},{"type":"DRUG","name":"Bimatoprost 0.03% Ophthalmic Solution","otherNames":["LUMIGAN®"]}],"arms":[{"label":"Bimatoprost 0.03% Formulation B Ophthalmic Solution","type":"EXPERIMENTAL"},{"label":"Bimatoprost 0.03% Ophthalmic Solution","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension","primaryOutcome":{"measure":"Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Bimatoprost 0.03% Formulation B Ophthalmic Solution","deltaMin":24.9,"sd":2.364},{"arm":"Bimatoprost 0.03% Ophthalmic Solution","deltaMin":24.86,"sd":2.161}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["23743437"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":301},"commonTop":["Conjunctival Hyperaemia"]}}